ResMed Inc. (RMD) 2024 Earnings Analysis
ResMed Inc.2024 Earnings Analysis
80/100
ResMed Inc.'s 10-K for the period ended June 30, 2024 shows a company with real operating weight: $4.69B of revenue, $1.02B of net income, and $1.30B of free cash flow. AirSense 11 CPAP Platform, Brightree / MEDIFOX-DAN, and CPAP Device Position remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. Gross margin was 56.7% and operating margin was 28.2%, so FY2024 does not look like a year bought with weak pricing or loose cost control. Per the FY2024 annual report and company disclosures, the business will likely be fine only if Philips Re-Entry and GLP-1 Speculation remain controlled simultaneously.
Core Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Earnings Quality
The significance of gross margin in FY2024 is that gross margin of 56.7% reflects the disclosed sleep apnea device and mask product mix.
Operating Margin is worth reading alongside the rest of the file because the 28.2% operating margin reflects the disclosed Sleep and Respiratory Care segment economics plus SaaS-segment operating leverage.
On cf / net income, the useful point is that OCF of $1.40B is 1.37x net income of $1.02B — reflecting depreciation and intangible-amortization on the MEDIFOX-DAN and Brightree acquisitions per the cash-flow reconciliation.
The reason FY2024 looks credible is that the accounting result and the cash result are moving together: $1.02B of net income came with $1.40B of operating cash flow and $1.30B of free cash flow. AirSense 11 CPAP Platform and Brightree / MEDIFOX-DAN give the filing a business explanation for why cash conversion stayed solid. The filing therefore looks like an operating story first and a financing story second: 28.2% operating margin, then cash conversion, then capital returns. Reported profit is converting into cash at a healthy rate, which reduces the odds that the FY2024 result is being flattered by accruals.
Moat Strength
CPAP Device Position is useful mainly because resMed's AirSense product family (AirSense 11 as described in the product launch) holds a leading share of the CPAP-device market per public industry-analyst coverage — Philips Respironics' competitive recall created a multi-year market-share opportunity as described in the industry communications.
Mask Recurring Revenue matters because mask sales (annual replacement cycle per insurance-reimbursement protocols as described in the customer-base communications) provide recurring-revenue anchored to the installed CPAP base.
What saas segment really tells you is that the SaaS segment (Brightree for HME / post-acute care + MEDIFOX-DAN for European post-acute care per the closing press releases) provides software-services revenue as described in the subscription model.
If you want the moat in plain language, start with AirSense 11 CPAP Platform and Brightree / MEDIFOX-DAN. CPAP Device Position and SaaS Segment help explain why the company can defend pricing or wallet share without needing a monopoly narrative. What matters is that 21.0% ROE did not require sacrificing the cash profile or the operating position. That is the practical moat test: a competitor has to dislodge behavior, not just underprice a SKU.
Capital Allocation
The allocation takeaway from free cash flow is that FCF of $1.30B (OCF $1.40B minus capex $99M) supports the disclosed share-repurchase, dividend, and selective-acquisition program.
MEDIFOX-DAN Acquisition is relevant because resMed acquired the German post acute care SaaS provider for approximately $1B as described in the transaction value.
On net debt position, the file suggests that long-term debt of $697M against $238M cash equals net debt of approximately $459M — modest as described in the capital-structure footnote.
The reason capital allocation matters here is simple: the business still threw off $1.30B of free cash flow after paying to maintain itself. Capex is modest at 2.1% of revenue, so the real decision is how management redeploys the cash left over. Liquidity is workable at $238M, but the debt stack at $707M keeps the company tied to continued cash generation. Per the FY2024 annual report and company disclosures, the payout framework uses both dividends and repurchases, which works only while cash generation remains solid.
Key Risks
The risk significance of philips re-entry is that philips' eventual return to the CPAP market would intensify competitive pressure as described in the competitive-landscape footnote.
GLP-1 Speculation belongs on the watch list because GLP 1 class drugs' weight-loss effects could reduce moderate obstructive sleep apnea (OSA) severity in some patient populations — a long-tail risk to CPAP-device demand as described in the Risk Factors discussion.
The point of reimbursement pressure is that reimbursement levels for CPAP devices and masks are set by Medicare / Medicaid and commercial payers as described in the payer-mix communications — pricing pressure is an ongoing risk.
The filing makes the risk picture look cumulative rather than binary. The risk file matters because several modest problems can still compound into a weaker cash outcome. Acquisition discipline remains relevant with goodwill at 41.4% of assets. Per the FY2024 annual report and company disclosures, the business will likely be fine only if Philips Re-Entry and GLP-1 Speculation remain controlled simultaneously.
Management
Ask about this section
This analysis is for educational purposes only and does not constitute investment advice.